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Abstract
Background: Artemisinin and its derivatives were reported to possess strong regulatory effects on inflammation and
autoimmune diseases. This study was designed to examine the therapeutic effects and underlying mechanisms of SM934, a
water-soluble artemisinin analogue, on lupus-prone female NZB6NZW F1 mice.
Methodology/Principal Findings: NZB/W F1 mice were treated orally with SM934 for 3 or 6 months respectively to
investigate the effect on clinical manifestations and immunological correlates. To further explore the mechanisms of SM934,
ovalbumin (OVA)-immunized or interferon (IFN)-c-elicited C57BL/6 mice were used. In vivo, treatment with SM934 for 3 or 6
months significantly delayed the progression of glomerulonephritis and increased the survival rate of NZB/W F1 mice.
Clinical improvement was accompanied with decreased Th1-related anti-double-strand DNA (dsDNA) IgG2a and IgG3 Abs,
serum interleukin (IL)-17, and increased Th2-related anti-dsDNA IgG1 Ab, serum IL-10 and IL-4. SM934 treatment also
suppressed the accumulation of effector/memory T cells, induced the apoptosis of CD4
+ T cells, while enhancing the
development of regulatory T cells in NZB/W F1 mice. In addition, SM934 treatment promoted the IL-10 production of
macrophages from NZB/W F1 mice, OVA-immunized C57BL/6 mice and IFN-c-elicited C57BL/6 mice. In vitro, SM934
enhanced IL-10 production from primary macrophages stimulated with IFN-c.
Conclusions/Significance: The results of this study demonstrated that artemisinin analogue SM934 had therapeutic effects
on lupus-prone female NZB/W F1 mice by inhibiting the pathogenic helper T cell development and enhancing anti-
inflammatory cytokine IL-10 production.
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Introduction
Systemic lupus erythematosus (SLE) is a chronic autoimmune
disease characterized by abnormal accumulation of autoreactive T
lymphocytes and production of autoantibody against self-antigen,
which result in the development of immune complex-mediated
glomerulonephritis and renal failure [1,2]. Female NZB/W F1
mice resemble human lupus closely. This strain of mice
spontaneously develops severe autoimmune disease, especially
the fatal immune complex-mediated glomerulonephritis, around 5
to 7 months of age, and approximately 50% die by 8 months and
90% die by 12 months of age [3,4]. It’s well documented that
activated/memory helper T cells (CD4
+CD44
+CD62L
2 effector
T cells, Teff), especially IFN-c-producing Th1 subset, are
responsible for inciting human and murine lupus, in part through
increased production of highly nephritogenic Th1-related Ig2a
and IgG3 autoantibodies [5–8]. With the development of
pathogenic helper T cells, CD4
+Foxp3
+ regulatory T cells (Treg)
failed to maintain a competitive pool size in the peripheral
lymphoid organs, finally resulting in a progressive imbalance of
Treg and Teff [9–11].
The recently defined IL-23/IL-17 axis, as well as the IL-12/
IFN-c axis, is emerging to be critical in many autoimmune
diseases [12,13]. IL-23 can directly elicit IL-17 family cytokines
from memory helper T cells and other innate immune cells
[12,13], especially the cd T cells [14,15]. In addition to recruiting
neutrophils, recent evidences also strongly suggest that IL-23/IL-
17 axis can exert its function by orchestrating adaptive Th1
responses in inflammatory bowel disease [16,17], delayed type
hypersensitivity [17,18], and intracellular bacterial infection [19].
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e32424Currently, there are compelling evidences for a pathogenic role of
IL-17 in human lupus patients and lupus-prone female MRL/lpr
mice [20,21]. However, the definite IL-17-producing cells and
pathogenic role of IL-17 in lupus are still uncertain.
Disease severity in human and murine lupus is also tightly
correlated to IL-10 [22]. It was reported that patients with lupus
produced large amount of IL-10 [23,24]. Administration of anti-
IL-10 mAb to human patients with active lupus [25] or NZB/W
F1 mice [26] led to the amelioration of disease activity. However,
there were also some reports supporting a protective role of IL-10
in SLE. For example, in MRL/lpr mice, deficiency of IL-10
resulted in exacerbated disease, demonstrated by enhanced Th1
cell development and increased mortality [27]; Over-expression of
IL-10 in lupus-prone NZM2410 mice could ameliorate lupus
diseases [28]. Routinely, IL-10 is deemed a regulatory cytokine.
IL-10 could inhibit IFN-c production and proliferation of CD4
+ T
cells through its direct inhibitory effects on T cells or indirect
inhibitory effects on antigen-presenting cells [29]. Many cells
produce IL-10, especially the myeloid cells, and IL-10 released
from myeloid cells can maintain Foxp3 expression and suppressive
function of Treg cells in a paracrine manner [30]. Thus, the role of
IL-10 remains controversial in SLE.
Multifactorial pathogenesis resulted in scarcity of therapeutic
approaches for SLE. Artemisinin derivatives possess strong anti-
inflammatory and immunosuppressive functions, and have shown
significant therapeutic effects on SLE clinically and experimentally
[31–38]. SM934, b-aminoarteether maleate, was synthesized from
b-hydroxyarteether at Shanghai Institute of Materia Medica.
Chemically, as the derivative of artemisinin, SM934 also contains
the unique peroxide bridge, but has higher bioavailability.
Recently, we demonstrated that in vitro SM934 could suppress
the Th1 and Th17 polarization, but exerted no influence on Treg
differentiation; In vivo, SM934 could significantly ameliorate lupus
diseases in MRL/lpr mice through inhibiting the both of Th1 and
Th17 responses, and elevating Treg percentage [38]. In MRL/lpr
mice, the lpr (lymphoproliferative) mutation of the fas gene impairs
activation-induced cell death (AICD), which results in the
abnormal accumulation of autoreactive T, B and double negative
T lymphocytes (CD3
+CD4
2CD8
2B220
+ cells) [39]. However, in
NZB/W F1 mice, the fas gene is intact, which makes the
pathogenesis of NZB/W F1 mice largely different from that of
MRL/lpr mice. In this study, we explored the therapeutic effects
and underlying mechanisms of SM934 on NZB/W F1 mice and
demonstrated that SM934 could exert comprehensive therapeutic
effects on NZB/W F1 mice both in short-term and long-term
treatment. SM934 treatment could significantly increase Treg
percentage and suppress the Th1 and Th17 responses in NZB/W
F1 mice. Although our previous report suggested that SM934
could induce activated CD4
+ T cells into apoptosis in vitro [34], it’s
hardly to present such effects of SM934 in vivo, for that, usually
apoptotic cells will be phagocytized and cleared quickly. Herein,
through flow cytometric staining surface B220 and western blot
analysis of Bcl-2 protein expression in the CD4
+ T cells, we firstly
demonstrated that SM934 treatment could prompt the apoptosis
of activated CD4
+ T cells in vivo. Furthermore, the therapeutic
effects of SM934 on NZB/W F1 mice were tightly linked to
enhancing IL-10 production from macrophages, which was absent
in MRL/lpr mice.
Collectively, the results of this study demonstrated the
therapeutic effects of artemisinin derivative SM934 on female
NZB/W F1 mice with established nephritis. SM934 treatment
could correct pathogenic helper T cell commitment and enhance
IL-10 production that might be beneficial for future lupus
treatment.
Results
Therapeutic effects of SM934 on female NZB/W F1 mice
with three months oral administration
Female NZB/W F1 mice develop kidney inflammation
gradually from about 5 months old on. Here, we used 6.5
months old female NZB/W F1 mice with ongoing kidney injury,
which was demonstrated by about 26% of mice with severe
proteinuria scored $3+. As shown in Figure 1A, with aging,
vehicle treated mice progressively developed severe proteinuria,
manifested by absolute urinary protein concentration (Up-panel)
and percentage of severe proteinuria scored $3+ (Bottom-panel),
and peaked nearly at the age of 8 months. SM934 treatment,
both 10 and 3 mg/kg, could dramatically inhibit the progression
and aggravation of proteinuria, as quickly as 2 (for 10 mg/kg) to
4 weeks (for 3 mg/kg) after treatment. Meanwhile, SM934 at the
dose of 1 mg/kg also presented mild therapeutic effects. In
addition, all three doses of SM934 could maintain the body-
weight of lupus-suffered mice during treatment, in which 10 and
3 mg/kg showed statistical significance at indicated time point
(Figure 1B). At the end of 3 months of treatment, mice were
sacrificed and examined for blood urea nitrogen (BUN). Results
showed that SM934 (10 mg/kg) and prednisolone (PNS)
treatment significantly decreased the BUN levels (Figure 1C).
Accumulated survival rate showed that SM934 treatment,
especially at the dose of 10 mg/kg, could significantly decrease
the death rate (p,0.05, Figure 1D). Kidneys were examined to
evaluate renal pathology and IgG deposition. Histological
sections from vehicle treated mice exhibited severe renal
damage, characterized by glomerular sclerosis, hyalinosis,
increased mesangial matrix, diffused perivascular and interstitial
mononuclear cell infiltration, tubular atrophy, and accumulation
of proteinaceous casts in the tubules. Mice treated with SM934
(10 and 3 mg/kg) presented significantly less severe renal
damage that showed marked amelioration in glomerular,
perivascular injuries, and interstitial inflammatory cell infiltra-
tion and lesion (representative histopathological pictures in
Figure 2, Left panel and detailed individual histological score
was listed in Table S1).
Renal cryostat sections were stained for detecting IgG
deposition. The pronounced mesangial IgG deposits were shown
in kidneys from vehicle treated mice. In contrast, mice treated with
SM934 (10 and 3 mg/kg) showed remarkably diminished IgG
deposition (representative immunofluorescence pictures in
Figure 2, Right panel and detailed individual score was listed in
Table S1).
Effects of SM934 treatment on the sera levels of
autoantibodies and cytokines in female NZB/W F1 mice
Anti-dsDNA IgG autoantibodies, especially Th1-related
IgG2a and IgG3 isotypes, are hallmarks of SLE and play
important pathogenic roles in lupus nephritis [5–8,40].
However, Th2-related IgG1 isotype might play a protective
role in murine and human lupus through preferentially
stimulating inhibitory FccR [40,41]. The serum levels of anti-
dsDNA antibodies were examined and shown in Figure 3A.
Three months SM934 treatment, at the doses of 10 and 3 mg/
kg, largely decreased total anti-dsDNA IgG Ab (p=0.13 and
p=0.05, respectively), IgG2a isotype (both p,0.05) and IgG3
isotype (p=0.12 and p=0.09, respectively), but significantly
increased the level of IgG1 isotype (p,0.01 and p=0.09,
respectively).
The serum levels of cytokines were shown in Figure 3B. SM934
treatment, at the doses of 10 and 3 mg/kg, significantly increased
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of 10 mg/kg, SM934 significantly decreased the serum level of IL-
17A (P,0.05). However, SM934 treatment exerted no influence
on serum transforming growth factor-b (data not shown).
SM934 treatment prompted the apoptosis of CD4
+ T cells
After 3 months of treatment, splenocytes were obtained to
examine the immunologic correlates. Flow cytometry analysis
showed that SM934 treatment did not influence the percentage of
major cellular population in spleens including CD4
+ T cells, CD8
+
T cells, B cells, dendritic cells, and monocytes (Table S2). For that
our previous study showed that in vitro SM934 could exclusively
induce activated, not naı ¨ve, CD4
+ T cell into apoptosis [34], we
then examined the B220 expression on the surface of CD4
+ T
cells, which was reported to be the apoptotic marker for activated
CD4
+ T cells [42,43]. Dramatically, SM934 treatment signifi-
cantly enhanced the accumulation of CD4
+B220
+ population in
the spleen (Figure 4A and 4B). Furthermore, western blot analysis
showed that SM934 treatment decreased the Bcl-2 protein level in
purified CD4
+ T cells (Figure 4C).
SM934 treatment induced the accumulation of
regulatory T cells
Our previous study showed that, in vitro, SM934 will not
influence the differentiation of Treg cells, but could favor the
accumulation of Treg cell in the spleens of MRL/lpr mice in vivo.
We then examined the FoxP3 expression in the splenocytes.
Results showed that SM934 treatment significantly enhanced the
accumulation of CD4
+FoxP3
+ Treg cells in the spleens, regarding
both intracellular FoxP3 protein (Figure 5A and 5B) and FoxP3
mRNA levels (Figure 5C) in CD4
+ T cells.
Effects of SM934 treatment on the balance of pro-
inflammatory and anti-inflammatory cytokines
To confirm the influence of SM934 treatment on the
development of pathogenic T cells, splenocytes were ex vivo
stimulated with anti-CD3 mAb. Results showed that splenocytes
of SM934 treated mice produced higher IL-10 and IL-4, and less
IL-17 and IFN-c, compared with vehicle treated ones (Figure 6A).
To clarify the major cellular source of IL-10, splenocytes were
directly stimulated with PMA and ionomycin and examined by
Figure 1. SM934 treatment for 3 months improved lupus syndroms. Six and half months old female NZB/W F1 mice were orally treated with
vehicle (saline), SM934 (10, 3, and 1 mg/kg, respectively), and PNS (2 mg/kg) for 3 months (n=11 per group). (A) Up: levels of proteinuria; Bottom:
frequencies of mice with severe proteinuria (urinary protein $3 mg/ml). (B) Body weight. (C) Serum levels of blood urea nitrogen (BUN) immediately
measured at the end of experiment. (D) Cumulative survival rate during 3 months of treatment. a=P,0.05; b=P,0.01 versus vehicle.
doi:10.1371/journal.pone.0032424.g001
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shown in Figure 6B, SM934 treatment significantly enhanced
CD11b
+F4/80
+ macrophages, but not CD11b
+CD11c
+, CD4
+,
CD8
+, B220
+ cells (data not shown), to produce IL-10. Further-
more, flow cytometric analysis showed that SM934 treatment
reduced the accumulation of IFN-c-producing CD4
+ T cells
(Figure 6C) and IL-17-producing CD3
+ T cells in the spleens
(Figure 6D, Up-panel). Through co-staining of different surface
markers, we identified that SM934 treatment only decreased the
percentage of IL-17
+ population in CD3
+cd
2 T cells, but not in
CD3
+cd
+ T cells (Figure 6D, Bottom-panel).
SM934 treatment induced IL-10 production from
macrophage in OVA-immunized mice
To further confirm the effect of SM934 that induced higher
production of IL-10 in macrophages, OVA/CFA-immunized
female C57BL/6 mice were treated with SM934 (10 mg/kg) or
vehicle for 7 days. Then, the splenocytes were obtained and
stimulated with or without OVA recall. Compared with
splenocytes from vehicle treated mice, splenocytes from SM934
treated mice produced more IL-10 (Figure 7A). In addition,
purified F4/80
+ splenic macrophages from SM934 treated mice
showed the suppressive effect on the proliferation of co-cultured
CD4
+ T cells purified from vehicle treated mice under OVA-recall
stimulation (Figure 7B).
SM934 induced IL-10 production from macrophage
elicited by IFN-c in vitro and in vivo
Enriched primary peritoneal macrophages obtained from naı ¨ve
female C57BL/6 mice were in vitro stimulated with or without
IFN-c to further determine the effect of SM934. The results
showed that SM934 (10 mM) could directly enhance IL-10
production and suppress IL-12/23p40 production in primary
peritoneal macrophages with IFN-c stimulation (Figure 8A).
To further confirm the IL-10-inducing ability of SM934 on
IFN-c-stimulated macrophages, we i.p. challenged the mice with
IFN-c and treated them with SM934 for 3 days. As shown in
Figure 8B, ex vivo, SM934 treatment also significantly enhanced
IL-10 production and suppressed IL-12/23p40 production from
peritoneal macrophages.
Long-term treatment of SM934 gained more valuable
therapeutic effects on female NZB/W F1 mice
To examine the long-term therapeutic effects of SM934, 6.5
months old female NZB/W F1 mice were treated with SM934 for
6 months at the dose of 10 mg/kg. Results showed that, with
aging, vehicle treated mice developed severe proteinuria accom-
panied with progressive bodyweight loss. Compared with vehicle
group, SM934 treatment significantly suppressed the progressive
elevation of proteinuria level (Figure 9A) and ameliorated the loss
of bodyweight (Figure 9B) during 6 months treatment period.
Accumulated survival rate showed that SM934 treatment
significantly prolonged the lifespan (Figure 9C). After 5.5 months
treatment (at the age of 12 months), all mice in vehicle group died,
while nearly 50% in SM934 treated group was still alive even after
6 months treatment. At the termination of this 6 months
treatment, all remained mice were humanely sacrificed, and
kidneys were removed for histological evaluation. As shown in
Figure 9D, SM934 treatment significantly alleviated the kidney
lesions, especially for decreased glomerular mesangial prolifera-
tion, basement membrane proliferation, glomerular sclerosis,
tubular dilatation, and perivascular injuries, but exerted minor
influence on interstitial inflammatory (detailed histological score
was listed in Table S3).
Discussion
In this study, we explored the therapeutic effects and
mechanisms of SM934 on autoimmune syndrome in lupus-prone
female NZB/W F1 mice. Results of this study showed that SM934
treatment could significantly reverse the imbalance of Th1/Th2-
related anti-dsDNA autoantibodies level, correct the abnormal
development of helper T cells, reduce the immune complex
deposition, ameliorate the lethal renal injury, and thus prolong the
lifespan of female NZB/W F1 mice. Remarkably, the therapeutic
effects of SM934 were also tightly linked to the enhanced
production of IL-10 from macrophages.
In murine lupus, IgG2a autoantibody selectively binds activa-
tory FccRIV, while IgG1 isotype preferentially engages inhibitory
FccRIIb [40,41]. IgG3 autoantibody is the most potent isotype to
Figure 2. SM934 treatment for 3 months improved kidney
injuries and IgG depositions. Six and half months old female NZB/W
F1 mice were orally treated with vehicle (saline), SM934 (10, 3, and
1 mg/kg, respectively), and PNS (2 mg/kg) for 3 months (n=11 per
group). Left, representative kidney sections stained with H&E (Original
magnification6200); Right, representative immunofluorescence stain-
ing of IgG deposit in the kidney sections (Original magnification6100).
doi:10.1371/journal.pone.0032424.g002
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SM934 could significantly suppress the serum levels of IgG2a and
IgG3 anti-dsDNA autoantibodies, while increase the IgG1 anti-
dsDNA subclass, which might largely contribute to the disease
alleviation. However, 10 mg/kg SM934 was less effective to
suppress the total anti-dsDNA IgG antibody level than 3 mg/kg
SM934 did, which might be resulted from the elevated IgG1
subclass. Despite the less potency in suppressing serum total anti-
dsDNA autoantibody, 10 mg/kg SM934 exerted similar inhibitory
effects with 3 mg/kg SM934 on IgG deposit in the kidneys. Such
inconsistency between serum total anti-dsDNA autoantibody level
and IgG deposit in the kidney seems to be acceptable, for that,
recently, Hughes et al also reported this phenomenon in
progesterone treated NZB/W F1 mice [44].
IL-17 was found to be an important pathogenic factor in murine
and human lupus. In the current report, we also found that there
was a high concentration of IL-17 in the serum, and that the
therapeutic effects of SM934 were tightly linked with its inhibiting
serum IL-17 in NZB/W F1 mice. However, the definite cellular
source of IL-17 was still elusive in NZB/W F1 mice, considering
that both Th17 cells and innate-like IL-17-producing cd T cells
were reported to be major IL-17 producers in many autoimmune
diseases [14,15]. In this study, we found that most of IL-17
+ cells in
the spleen were CD3
+TCRcd
2 T cells, which suggested that
Th17, rather than cd T cells were major IL-17 producers at the
later stage of disease. SM934 could significantly suppress the
development of Th17 cells and decrease serum IL-17 level, but did
not exert influence on IL-17
+cd T cells. Thus, this study supported
that Th17 cells might play an important pathogenic role in lupus
diseases.
This pharmacological study also argued the role of so-called
pathogenic role of IL-10 in the pathogenesis of lupus. Some
published work reported that, in lupus, pathogenic T cells were
comprehensive activated and less sensitive to the suppression of
Treg or IL-10 [45–47]. Recently, Yuan et al demonstrated that the
response of monocytes from lupus patients were less sensitive to
the suppression of IL-10 [48]. Here, although we did not compare
the sensitivity of Teff cells to Treg and IL-10 between vehicle and
SM934 treated groups, we still presumed that simultaneously
regulating balance of effector T, naı ¨ve T, and regulatory T cells
Figure 3. SM934 treatment regulated anti-dsDNA autoantibodies and cytokines in sera. At the termination of 3 months treatment, sera of
female NZB/W F1 mice were collected and examined for anti-dsDNA autoantibodies and cytokines. (A) Serum levels of anti-dsDNA total IgG, IgG1,
IgG2a and IgG3 antibodies. Sera of 10 months old female NZB/W F1 mice were used as the standard control. (B) Serum levels of IL-10, IL-4, IL-17A and
IFN-c. Shown were mean 6 SEM. *=P,0.05; **=P,0.01 versus vehicle.
doi:10.1371/journal.pone.0032424.g003
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disease remission. In addition, from the current study and other
reports, we propose that IL-10 still work as an immunosuppressive
factor, whereas the final readout of the suppressive effects of IL-10
will be determined by the pathogenic status of other responsive
cells.
In vivo, SM934 treatment could induce the accumulation of Treg
cell in peripheral. However, this inducible effect was not likable to
be direct. Our previous work showed that, in vitro, SM934 could
suppress Th1 and Th17 cell differentiation, but exerted no
suppressive influence on Treg cell differentiation. Certainly, in
vitro, SM934 will not induce FoxP3 expression in CD4
+ T cells. In
vitro, we also compared the effects of SM934 on the proliferation of
CD4
+CD25
2 and CD4
+CD25
+ T cells isolated from naı ¨ve
C57BL/6 mice, and finally found that SM934 suppressed the
Figure 4. SM934 treatment induced the apoptosis of CD4
+ T
cells. At the termination of 3 months treatment, female NZB/W F1 mice
in vehicle and SM934 (10 mg/kg) treated groups were randomly and
averagely divided into 3 sub-groups. Spleens of each sub-group were
pooled together. (A) Representative staining of surface CD4 and B220 in
splenocytes. (B) Statistical results of percentage of CD4
+B220
+
population in splenocytes. (C) CD4
+ T cells were purified through
magnetic negative selection and examined for Bcl-2 expression through
western blot analysis. One blot was the mix of two equal splenic
samples from treated groups. Shown are mean 6 SD, n=3 in each
treated group. *=P,0.05 versus vehicle.
doi:10.1371/journal.pone.0032424.g004
Figure 5. SM934 treatment induced the accumulation of Treg
cells. At the termination of 3 months treatment, female NZB/W F1 mice
in vehicle and SM934 (10 mg/kg) treated groups were randomly and
averagely divided into 3 sub-groups. Spleens of each sub-group were
pooled together. (A) Surface CD4 and intracellular FoxP3 expressions in
splenocytes. (B) Statistical results of percentage of CD4
+FoxP3
+
population in splenocytes. (C) Real-time PCR analysis of FoxP3 mRNA
expression in purified CD4
+ T cells. Shown are mean 6 SD, n=3 in each
treated group. *=P,0.05 versus vehicle.
doi:10.1371/journal.pone.0032424.g005
Figure 6. SM934 treatment suppressed Th1 and Th17 cell
development and enhanced IL-10 production from macro-
phages. At the termination of 3 months treatment, female NZB/W F1
mice in vehicle and SM934 (10 mg/kg) treated groups were randomly
and averagely divided into 3 sub-groups. Spleens of each sub-group
were pooled together and ex vivo stimulated. (A) Cytokine productions
in splenocytes stimulated with anti-CD3 mAb for 24 hours. Shown are
mean 6 SD, n=3 in each treated group. (B) Flow cytometric analysis
showing intracellular IL-10 expression in CD11b
+F4/80
+ macrophages.
(C) Flow cytometric analysis of CD3
+IFN-c
+ cells in splenocytes. (D) UP-
panel, flow cytometric analysis of CD3
+IL-17
+ cells in splenocytes;
Bottom-panel, flow cytometric analysis of intracellular IL-17 associated
with surface CD4 and TCRcd expressions. For all flow cytometry plots,
shown are representative one of 3 samples with similar pattern in each
treated group. *=P,0.05, **=P,0.01 versus vehicle.
doi:10.1371/journal.pone.0032424.g006
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we suggested that, in vivo, SM934 treatment induced the apoptosis
of activated effector T cells, rather than preferably inducing Treg
accumulation, then accelerated the replenishment of CD4
+ T cell
pool consisting of more naı ¨ve population.
Collectively, this study demonstrated that artemisinin derivative
SM934 exerted valuable therapeutic effects on lupus-prone female
NZB/W F1 mice and possessed the great potential for future lupus
treatment. The therapeutic mechanism of SM934 might be
attributed to its regulating development of helper T cell subsets
and enhancing IL-10 production.
Materials and Methods
Animal experiments
Female NZB/W F1 mice were purchased from the Jackson
Laboratory. Female C57BL/6 mice were obtained from Shanghai
Laboratory Animal Center of the Chinese Academy of Sciences,
and were used at 7 to 10 weeks of age. All mice were housed under
specific pathogen-free conditions. Experiments were carried out
according to the National Institute of Healthy Guide for Care and
Use of Laboratory Animals and were approved by the Institutional
Animal Care and Use Committee at the Shanghai Institute of
Materia Medica, Chinese Academy of Sciences (IACUC protocol
# 2010-10-ZJP-01).
NZB/W F1 mice
Six and half months old female NZB/W F1 mice were orally
treated with SM934 for 3 months or 6 months respectively. At the
initiation of treatment, mice were randomly divided according to
bodyweight and proteinuria level and were orally treated for
consecutive 6 days every week. In 3 months treatment, mice were
divided into 5 groups (n=11 per group): vehicle control group
(saline), positive control group (prednisolone, PNS, 2 mg/kg/day),
and SM934 treated groups (10, 3, and 1 mg/kg/day respectively),
and the bodyweight and proteinuria level were monitored weekly.
In 6 months treatment, mice were divided into 3 groups (n=12
per group): vehicle control group (saline), positive control group
(prednisolone, PNS, 2 mg/kg/day), and SM934 treated group
(10 mg/kg/day), and the bodyweight and proteinuria level were
monitored biweekly. During the treatment, individuals were
euthanized, then sera and kidneys were collected, if their urine
protein concentration .10 mg/ml for consecutive two weeks
accompanied by weight loss .20%. In this case, the last known
values for urinary protein and bodyweight were carried forward.
For investigations of effects of SM934 treatment on immunological
correlates, 3 months treatment experiments were carried out.
OVA-immunized C57BL/6 mice
Naı ¨ve female C57BL/6 mice were immunized with emulsive
OVA/CFA according to our previous method [34], then were
treated with saline or SM934 (10 mg/kg/day) for 7 days.
IFN-c elicited C57BL/6 mice
To investigate the effects of SM934 on IFN-c-primed peritoneal
macrophages in vivo, naı ¨ve female C57BL/6 mice were i.p. injected
with 300 units of mIFN-c according to the method described by
Takeda et al [49], and simultaneously orally administrated with
SM934 (10 mg/kg/day) for consecutive 3 days. Then, peritoneal
exudative cells were collected.
Biochemical parameters, serum anti-dsDNA antibody
detection, renal histopathology and
immunofluorescence
All examinations and scoring were carried out according to our
previous descriptions [38]. Briefly, urinary protein concentrations
Figure 7. SM934 treatment induced IL-10 production of
macrophages in OVA-immunized mice. Naı ¨ve female C57BL/6
mice were immunized with OVA/CFA and treated with vehicle or SM934
(10 mg/kg) for consecutive 7 days (9 mice per treated group). At the
termination of treatment, both groups were randomly and averagely
divided into 3 sub-groups. Spleens of each sub-group were pooled
together. (A) IL-10 production in splenocytes cultured with OVA recall
for 24 hours. (B) OVA-induced proliferation in CD4
+ T cells from vehicle
treated mice co-cultured with macrophages from vehicle or SM934
treated mice for 72 hours. Bars showed the mean 6 SD. **=P,0.01,
***=P,0.001 versus corresponding medium or vehicle control with
similar stimulatory condition.
doi:10.1371/journal.pone.0032424.g007
Figure 8. SM934 induced IL-10 production from IFN-c-chal-
lenged macrophages in vitro and ex vivo. (A) Peritoneal macro-
phages were isolated from naı ¨ve C57BL/6 mice and then were in vitro
stimulated with mIFN-c in the presence or absence of SM934 for
24 hours. IL-10 (UP-panel) and IL-12/23p40 (Bottom-panel) productions
in the supernatants were examined by ELISA. (B) C57BL/6 mice were i.p.
elicited with mIFN-c and orally administrated with vehicle or SM934
(10 mg/kg) for 3 days. Then, peritoneal macrophages were cultured
with medium for 24 hours and supernatant IL-10 (UP-panel) and IL-12/
23p40 (Bottom-panel) were examined by ELISA. Bars showed the mean
6 SD of 3 independent experiments. *=P,0.05, **=P,0.01,
***=P,0.001 versus corresponding medium or vehicle control with
similar stimulatory condition.
doi:10.1371/journal.pone.0032424.g008
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Urinary protein was scored according to the following criteria: 0/
trace, ,0.3 mg/ml; 1+, $0.3 mg/ml; 2+, $1 mg/ml; 3+,
$3 mg/ml; 4+, $10 mg/ml; Blood urea nitrogen (BUN)
concentration was determined by BUN test kit (Jianchen
biotechnology, Nanjing, China) according to the manufacturer’s
instructions; For ELISA detection of serum anti-dsDNA IgG and
isotypes, sera from aged female NZB/W F1 mice (10 months of
age) was used as the standard. Titers of standard serum were
defined as follows: total IgG, 1000 U/ml; IgG1, 170 U/ml;
IgG2a, 340 U/ml; IgG3, 270 U/ml; Formalin-fixed kidney
sections were embedded in paraffin and stained with hematoxylin
and eosin (H&E), then were graded by two independent renal
pathologists; Snap-frozen kidneys were used for immunofluores-
cence examination of IgG deposits.
Flow cytometric analysis
Surface marker and intracellular transcription factor staining
was conducted and analyzed according to our previous
methods [38]. For intracellular cytokine staining, cells were
incubated for 4 hours with phorbol 12-myristate 13-acetate
(PMA, 50 ng/ml) and ionomycin (750 ng/ml) in the presence
of Brefeldin A (BFA, 10 mg/ml). At the end of incubation,
suspended cells were collected. Adherent cells were treated with
10 mM EDTA-PBS solution (pH=7.2) for 5 minutes and then
collected. Suspended and adherent cells were mixed together
and blocked with FccR blocker before extracellular staining for
corresponding fluorescence-labeled surface antibodies. After
surface staining, cells were fixed, permeabilized and stained for
cytokines according to manufacturer’s instruction (FoxP3
Staining Buffer set was used).
The following reagents were used: FITC- and PE-anti-mCD4
(GK1.5), FITC- and PE-anti-mCD3 (145-2C11), biotinylated- and
FITC-anti-mTCRcd (GL3), biotinylated-anti-mB220 (RA3-6B2),
PE-anti-mCD8 (2.43), FITC- and PE-anti-mCD11c (HL-3),
biotinylated- and PE-anti-mCD11b (M1/70), FITC-anti-mGr-1
(RB6-8C5), FITC-anti-mIFN-c (XMG1.2), PE-anti-mIL-10
(JES5-16E3), PE-anti-mIL-17 (TC11-18H10), and PE-Rat IgG1
were all purchased from BD Pharmingen; FITC-anti-mF4/80
(BM8), PE-Cy5-anti-mouse/rat FoxP3 (FJK-16s), PE-Cy5- and
PE-Rat IgG2a, PE-Rat IgG2b, and FoxP3 Staining Buffer Set
were all purchased from eBioscience.
Figure 9. SM934 treatment for 6 months significantly prevented fatal nephritis and prolonged the lifespan. Six and half months old
female NZB/W F1 mice were orally treated with vehicle, SM934 (10 mg/kg), and PNS (2 mg/kg) for 6 months (n=12 per group). (A and B), The levels of
proteinuria (A) and bodyweight (B) were measured every two weeks. (C) Cumulative survival rate during 6 months of treatment. (D) Histology of
representative kidney sections stained with H&E (Original magnification6200). In A, B and C, a=P,0.05; b=P,0.01; c=P,0.001 versus vehicle.
doi:10.1371/journal.pone.0032424.g009
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Splenic CD4
+ T cell. Purified polyclonal CD4
+ T cells from
splenocytes were enriched as described previously [38].
Splenic and peritoneal macrophage. To isolate splenic
F4/80
+ macrophages, splenocytes were blocked with saturated
anti-m-CD16/32 (2.4G2, purified in-house), then reacted with
FITC-anti-m-F4/80 mAb. After extensive washing, cells were
incubated with anti-FITC microbeads (Miltenyi Biotec, Bergisch
Gladbach, Germany) and positively selected. To acquire highly
purified resulted cells, two rounds of positive selection were
conducted. Purity of resulted cells was determined by flow
cytometry analysis, and was consistently .98%.
To isolate peritoneal macrophages, naive female C57BL/6 mice
were elicited by i.p. injection of 0.5 ml of 3% thioglycollate
medium (TG, Difco, Detroit, MI). Three days later, adherent
peritoneal exudative cells were obtained by peritoneal lavage using
ice-cold phosphate-buffered saline, seeded in dishes, and collected
by removing the non-adherent cells after 2 hours incubation at
37uC. Peritoneal macrophages from mIFN-c-elicited C57BL/6
mice were enriched using similar protocol with thioglycollate-
elicited ones.
Cell stimulation and culture
Splenocytes from NZB/W F1 mice were cultured in 24-well flat-
bottom plates coated with anti-CD3 mAb (145-2C11, 5 mg/ml) for
24 hours. Splenocytes of OVA-immunized mice were stimulated
with OVA (100 mg/ml) for 24 hours. After incubation, superna-
tants were collected and stored at 220uC for ELISA assay.
Primary peritoneal macrophages were cultured in 48-well flat-
bottom plates and stimulated without or with 50 unit/ml mIFN-c
in the absence or presence of SM934 for 24 hours. After
incubation, supernatants were collected and stored at 220uC for
ELISA assay.
Purified CD4
+ T cells and F4/80
+ macrophages were cultured
together with the ratio of 4:1 in 96-well flat-bottom plates in the
presence or absence of OVA (100 mg/ml) for 72 hours. Cultures
were pulsed with 0.5 mCi
3H thymidine per well for 8 hours before
harvesting and assessed for
3H thymidine incorporation at
72 hours.
Real-time PCR
Total RNA was isolated using Trizol reagent (Invitrogen,
Carlsbad, CA, USA), reverse transcribed, and polymerase chain
reaction amplified using specific primers. Real-time PCR was
performed with SYBR Green PCR Reagents (Qiagen, Valencia,
CA, USA) and a Continuous Fluorescence Detection System (MJ
Research, USA), according to the manufacturer’s instructions.
Relative quantitation of mRNA expression was calculated as the
fold increase in expression by using the DDCt method. The
forward and reverse primers for FoxP3 and HPRT were as
follows: FoxP3 forward 59-CCC ATC CCC AGG AGT CTT G-
39, FoxP3 reverse: 59-ACC ATG ACT AGG GGC ACT GTA-39;
HPRT forward: 59-GTT GGA TAC AGG CCA GAC TTT
GTT G-39, HPRT reverse: 59-GAG GGT AGG CTG GCC TAT
AGG CT-39.
ELISA for cytokines detection
Cytokines in sera or culture supernatants were assayed using the
mouse IL-10, IL-12/23p40, TGF-b, IFN-c, IL-2, IL-4, IL-17A
ELISA kit (all from BD Pharmingen) according to the manufac-
turer’s instructions.
Western blot
Purified CD4
+ T cells from mice of different groups were
directly lysed in SDS sample buffer and boiled for 5 min at 100uC.
Proteins were resolved by 10% SDS-polyacrylamide gel electro-
phoresis (PAGE), transferred to the nitrocellulose membrane
(Amersham Pharmacia Biotech, Buckinghamshire, UK). The
membranes were treated with 5% BSA-TBST buffer (TBS
containing 0.1% Tween20) for 2 hours to block nonspecific
binding, rinsed, and incubated with anti-BCL-2 (SC-492, Santa
Cruz Biotechnology) or anti-GAPDH (Cell Signaling Technology).
Signals were detected with HRP-conjugated anti-rabbit or anti-
mouse IgG using the ECL system (Amersham Biosciences).
Statistical analysis
Data were analyzed using Student’s t-test and one-way analysis
of variance (ANOVA) with Newman-Keuls multiple comparisons
on post-tests. Nonparametric data (histological score) were
analyzed using Mann-Whitney U test. Survival rate for treated
group was compared with control group by log-rank test followed
by Bonferroni adjustment. P,0.05 was considered to be
statistically significant.
Supporting Information
Table S1 Glomerular, tubular, vascular, interstitial damage, and
glomerular IgG depositions were analyzed using a semiquantita-
tive scoring system and scored by two pathologists.
(DOC)
Table S2 * P,0.05, ** P,0.01 versus vehicle.
(DOC)
Table S3 Glomerular, tubular, vascular, and interstitial damages
were analyzed using a semiquantitative scoring system: 2,n o
changes; 6, minimal changes; +, mild changes; ++, moderate
changes; +++, marked changes.
(DOC)
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